Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation

被引：23
|
作者：
Cutting, Rob [1 ]
Mirelman, Anna [1 ]
Vora, Ajay [1 ]
机构：
[1] Sheffield Childrens Hosp, Dept Paediat Haematol, Sheffield S10 2TH, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2008年 / 143卷 / 05期
关键词：
child; allogeneic transplant; treosulphan; conditioning;
D O I：
10.1111/j.1365-2141.2008.07399.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：748 / 751
页数：4
相关论文
共 50 条
  • [41] Comparison of the feasibility of adult allogeneic umbilical cord blood transplantation between the myeloablative conditioning regimen and the non myeloablative one.
    Tashiro, H
    Kozai, Y
    Noguchi, M
    Goto, M
    Kawasugi, K
    Kodo, H
    Shirafuji, N
    BLOOD, 2004, 104 (11) : 378B - 378B
  • [42] Pharmacokinetics of treosulfan in a myeloablative conditioning combination with cyclophosphamide prior to allogeneic haematopoietic stem cell transplantation
    Hilger, RA
    Scheulen, ME
    Trenschel, R
    Seeber, S
    Beelen, DW
    BONE MARROW TRANSPLANTATION, 2004, 33 : S173 - S174
  • [43] Reduced Intensity Versus Myeloablative Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
    Fan, Donna
    Sabry, Waleed
    Stakiw, Julie
    MacKay, Rebecca Ellyn
    Bosch, Mark
    Sarker, Sabuj
    Elemary, Mohamed
    BLOOD, 2014, 124 (21)
  • [44] Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation
    Nygaard, M.
    Hovgaard, D.
    Schjodt, I. M.
    Andersen, N. S.
    Vindelov, L.
    Sengelov, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (03) : 358 - 361
  • [45] ONCE DAILY INTRAVENOUS BUSULPHAN PLUS FLUDARABINE IS A SAFE LESS TOXIC CONDITIONING FOR AML AND MDS ALLOGENEIC TRANSPLANTATION
    Baronciani, D.
    Depau, C.
    Targhetta, C.
    Di Tucci, A. A.
    Tandurella, I.
    Angelucci, E.
    HAEMATOLOGICA, 2015, 100 : 175 - 176
  • [46] Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas
    Othman, Tamer
    Moskoff, Benjamin N.
    Esteghamat, Naseem
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Jonas, Brian A.
    Abedi, Mehrdad
    Richman, Carol
    Tuscano, Joseph M.
    LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 231 - 234
  • [47] Myeloablative Conditioning Predisposes Patients for Toxoplasma gondii Reactivation after Allogeneic Stem Cell Transplantation
    Meers, Stef
    Lagrou, Katrien
    Theunissen, Koen
    Dierickx, Daan
    Delforge, Michel
    Devos, Timothy
    Janssens, Ann
    Meersseman, Wouter
    Verhoef, Gregor
    Van Eldere, Johan
    Maertens, Johan
    CLINICAL INFECTIOUS DISEASES, 2010, 50 (08) : 1127 - 1134
  • [48] Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies
    Connor, Matthew P.
    Loren, Alison W.
    Hexner, Elizabeth O.
    Martin, Mary Ellen
    Gill, Saar I.
    Luger, Selina M.
    Mangan, James K.
    Perl, Alexander E.
    McCurdy, Shannon R.
    Pratz, Keith W.
    Timlin, Colleen
    Freyer, Craig W.
    Carulli, Alison
    Catania, Christopher
    Smith, Jacqueline
    Hollander, Lauren
    Zebrowski, Alexis M.
    Stadtmauer, Edward A.
    Porter, David L.
    Frey, Noelle, V
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (02): : 113 - 118
  • [49] Patients at risk for primary graft failure after allogeneic haematopoietic cell transplantation with myeloablative conditioning
    Olsson, R.
    Logan, B.
    Schriber, J.
    Zhu, X.
    Ringden, O.
    Cooke, K.
    Ho, V.
    McCarthy, P.
    Agovi, M.
    Chaudhury, S.
    Pasquini, M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S18 - S18
  • [50] Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome
    Juvonen, E
    Volin, L
    Koponen, A
    Ruutu, T
    BONE MARROW TRANSPLANTATION, 2002, 29 (05) : 457 - 458
12345